CNS Pharmaceuticals, Inc. (CNSP) - Dilution Analysis

S-3 filing: This filing relates to the resale of up to 9,793,479 shares of common stock by selling shareholders, including 650,000 existing shares and 9,143,479 shares issuable upon exercise of pre-funded warrants.

10-Q filing | 1.5M shares outstanding

8-K filing: CNS Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with institutional investors for a private placement of 650,000 shares of common stock at $2.30 per share and pre-funded warrants to purchase 9,143,479 shares of common stock at $2.299 per warrant, with gross proceeds of approximately $22.5 million. ($22.41M proceeds)

10-K filing | 0.8M shares outstanding

10-Q filing | 0.6M shares outstanding

10-Q filing | 0.6M shares outstanding

10-Q filing | 5.5M shares outstanding

8-K filing: CNS Pharmaceuticals, Inc. entered into a placement agency agreement for the public offering of 325,000 shares of common stock, pre-funded warrants to purchase 3,627,570 shares of common stock, and Series F Warrants to purchase up to 3,952,570 shares of common stock, with the closing occurring on May 14, 2025, and gross proceeds of approximately $5.0 million. ($5.0M proceeds)

S-1/A filing: CNS Pharmaceuticals, Inc. is offering up to 6,250,000 shares of common stock together with series F warrants to purchase up to 6,250,000 shares of common stock and pre-funded warrants to purchase up to 6,250,000 shares of common stock.

S-1 filing: CNS Pharmaceuticals, Inc. is offering up to 5,223,880 shares of common stock together with series F warrants to purchase up to 5,223,880 shares of common stock and pre-funded warrants to purchase up to 5,223,880 shares of common stock on a reasonable best efforts basis.

10-K filing | 2.9M shares outstanding

8-K filing: CNS Pharmaceuticals, Inc. increased the aggregate sales price of shares that may be sold under the Sales Agreement to $43.5 million and has sold 2,522,755 shares for gross proceeds of approximately $23.75 million as of March 20, 2025. ($23.75M proceeds)

8-K filing: Stock split 1-for-50 | Outstanding: 74,962,533 → 2

8-K filing: The company sold 17,475,827 shares of common stock pursuant to its at-the-market sales agreement and has 74,962,533 shares of common stock outstanding as of January 3, 2025.

10-Q filing | 57.5M shares outstanding

8-K filing: CNS Pharmaceuticals, Inc. entered into a placement agency agreement with A.G.P./Alliance Global Partners in connection with the sale of 3,700,000 shares of common stock and pre-funded warrants to purchase 13,947,060 shares of common stock in a registered direct offering, with gross proceeds expected to be approximately $3.0 million. ($2.99M proceeds)

10-Q filing | 32.1M shares outstanding

8-K filing: CNS Pharmaceuticals sold 23,091,315 shares of common stock for gross proceeds of approximately $9.9 million as of August 5, 2024, and has 25,959,589 shares of common stock outstanding. ($9.9M proceeds)

8-K filing: CNS Pharmaceuticals, Inc. entered into an agreement to issue 573,368 shares of common stock to Cortice Biosciences, Inc. upon closing and an additional 43,330 shares upon shareholder approval, as well as potential future issuances based on milestone achievements.

8-K filing: CNS Pharmaceuticals, Inc. sold 7,206,743 shares of common stock through A.G.P. for gross proceeds of approximately $5.19 million and increased the aggregate sales price of Shares that may be sold under the Agreement to $25.0 million. ($5.19M proceeds)

S-1/A filing: This S-1/A filing relates to a proposed offering of common stock and warrants. The company intends to raise additional funds through future equity or debt securities issuances.

S-1 filing: This prospectus relates to the resale of up to 2,359,000 shares of our common stock issuable upon exercise of certain outstanding common stock purchase warrants issued to the selling shareholders.

8-K filing: CNS Pharmaceuticals, Inc. entered into Securities Purchase Agreements with institutional investors for the sale of 1,425,000 shares of common stock at $1.39 per share in a registered direct offering and also sold unregistered warrants to purchase up to an aggregate of 1,425,000 shares of common stock in a concurrent private placement. ($1.98M proceeds)

8-K filing: CNS Pharmaceuticals, Inc. sold 568,000 shares of common stock and unregistered warrants to purchase up to 568,000 shares in a registered direct offering and concurrent private placement, with gross proceeds expected to be approximately $1.39 million. ($1.39M proceeds)

8-K filing: CNS Pharmaceuticals, Inc. entered into Securities Purchase Agreements for the sale of 336,000 shares of common stock and pre-funded warrants to purchase 30,000 shares of common stock, along with unregistered warrants to purchase up to 366,000 shares of common stock in a concurrent private placement. ($1.37M proceeds)

S-1 filing: CNS Pharmaceuticals, Inc. is offering common stock and warrants. There is no public market for the warrants being offered.

8-K filing: Stock split 1-for-50 | Outstanding: 11,851,932 → 325,000

10-Q filing | 11.9M shares outstanding

S-3 filing: CNS Pharmaceuticals, Inc. is offering up to $75,000,000 of common stock, preferred stock, debt securities, warrants, purchase contracts, or units of securities.

10-K filing | 10.6M shares outstanding

8-K filing: The Company completed a public offering of 2,215,667 shares of common stock, pre-funded warrants to purchase 11,117,667 shares of common stock, Series A Warrants to purchase up to 13,333,334 shares of common stock and Series B Warrants to purchase up to 13,333,334 shares of common stock, resulting in gross proceeds of approximately $3.7 million. ($3.7M proceeds)

S-1/A filing: This S-1/A filing relates to a reasonable best efforts offering where the company may amend certain outstanding warrants.

S-1/A filing: This S-1/A filing relates to a reasonable best efforts offering of common stock and warrants. The number of shares of common stock outstanding after this offering is based on 6,214,598 shares outstanding as of January 9, 2024.

S-1 filing: This S-1 filing outlines a reasonable best efforts offering of securities, including common stock, common warrants, and pre-funded warrants. The company's common stock is listed on The Nasdaq Capital Market under the symbol "CNSP."

S-3 filing: This S-3 filing registers 3,756,000 shares of common stock issuable upon exercise of inducement warrants for resale by a selling stockholder; CNS Pharmaceuticals will not receive any proceeds from the sale.

10-Q filing | 5.2M shares outstanding

10-Q filing | 3.9M shares outstanding

10-Q filing | 4.1M shares outstanding

10-K filing | 2.2M shares outstanding

8-K filing: CNS Pharmaceuticals, Inc. entered into a Securities Purchase Agreement for the sale of 147,000 shares of common stock, pre-funded warrants to purchase up to 1,742,764 shares of common stock, and warrants to purchase up to 1,889,764 shares of common stock in a public offering, with the closing expected on or about December 5, 2022. ($0.0M proceeds)

8-K filing: Stock split 1-for-30 | Outstanding: 40,032,481 → 1

10-Q filing | 40.0M shares outstanding

10-Q filing | 40.0M shares outstanding

10-Q filing | 40.0M shares outstanding

10-K filing | 40.0M shares outstanding

S-3 filing: Resale of 24,815,791 shares of common stock by selling stockholders.

8-K filing: CNS Pharmaceuticals, Inc. entered into a Securities Purchase Agreement for the sale of 9,489,474 shares of common stock, pre-funded warrants to purchase up to 2,615,790 shares of common stock, and warrants to purchase up to 12,105,264 shares of common stock in a private placement offering with gross proceeds expected to be approximately $11.5 million. ($11.5M proceeds)

10-Q filing | 27.9M shares outstanding

10-Q filing | 27.5M shares outstanding

8-K filing: The company sold 2,020,426 shares of common stock at an average price of $2.32 from June 4, 2021 to June 29, 2021, for gross proceeds of approximately $4.7 million and net proceeds of approximately $4.5 million. After the sales, the company will have 27,379,485 shares of common stock outstanding. ($4.7M proceeds)

10-Q filing | 25.4M shares outstanding

10-K filing | 23.9M shares outstanding

S-3 filing: CNS Pharmaceuticals, Inc. may from time to time issue up to $75,000,000 aggregate dollar amount of common stock, preferred stock, debt securities, warrants or units of securities.

8-K filing: CNS Pharmaceuticals, Inc. completed a public offering of 5,750,000 shares of common stock (including over-allotment) and warrants to purchase 2,875,000 shares, generating net proceeds of approximately $10.5 million. ($11.5M proceeds)

S-1/A filing: This S-1/A filing describes CNS Pharmaceuticals' intention to raise capital through the sale of common stock and warrants, with Lincoln Park Capital Fund committing to purchase up to $15.0 million worth of common stock, and the company intending to use the proceeds primarily to fund development costs for Berubicin and for working capital.

S-1 filing: This S-1 filing details an offering of 3,460,208 shares of common stock and pre-funded warrants, with an over-allotment option for an additional 519,031 shares, to fund development costs for Berubicin and for working capital.

10-Q filing | 16.5M shares outstanding

S-1 filing: This prospectus relates to the offer and sale of up to 2,100,000 shares of our common stock by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder.

8-K filing: CNS Pharmaceuticals, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, pursuant to which Lincoln Park has committed to purchase up to $15.0 million worth of the Company's common stock, and the Company issued 201,991 shares of Common Stock to Lincoln Park as commitment shares.

10-Q filing | 16.5M shares outstanding

10-Q filing | 16.5M shares outstanding